A Case of Protein-losing Enteropathy Treated with High Dose Intravenous Glucocorticoid Therapy in Systemic Lupus Erythematosus

2005 ◽  
Vol 22 (2) ◽  
pp. 253 ◽  
Author(s):  
Kyu Hyung Lee ◽  
Chang Mo Kwon ◽  
Hyun Do Kim ◽  
Dae Young Yun ◽  
Jae Yoong Lee ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Glucocorticoid Therapy ◽  
High Dose ◽  
Systemic Lupus ◽  
Protein Losing Enteropathy

scholarly journals Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Systemic Lupus Erythematosus

2013 ◽  
Vol 2 (2) ◽  
pp. 39-43
Author(s):  
Mojdeh Zabihi Yeganeh ◽  
Saeideh Sadeghi
Keyword(s):  
Diabetes Mellitus ◽  
Systemic Lupus Erythematosus ◽  
Mycophenolate Mofetil ◽  
Family History ◽  
Old Age ◽  
Lupus Erythematosus ◽  
Glucocorticoid Therapy ◽  
High Dose ◽  
Systemic Lupus ◽  
History Of

Background: The aim of this study was to investigate the prevalence and associated factors of glucocorticoid-induced Diabetes mellitus (GIDM) in patients with systemic lupus erythematosus (SLE) under glucocorticoid therapy.Methods: Patients with SLE who had received high-dose glucocorticoid therapy (prednisolone≥1 mg/kg/day) at Rasoul Akram and Firoozgar hospitals were recruited during 2006-2011.Results: A total of 81 patients with SLE were evaluated. 21 patients (25.9%) of them developed GIDM after high-dose glucocorticoid therapy. Univariate analysis of data showed that old age, family history of diabetes mellitus (DM) and use of Mycophenolate mofetil were factors that would increase the likelihood of GIDM.Conclusion: In summary, GIDM was developed among 25.9% of patients with SLE after high-dose glucocorticoid therapy. Old age, family history of DM and use of Mycophenolate mofetil were determined to be factors responsible for increasing the risk of developing GIDM.

Protein-losing enteropathy associated with systemic lupus erythematosus: response to cyclophosphamide

2004 ◽  
Vol 25 (2) ◽  
pp. 135-138 ◽  
Author(s):  
Gl�ucio R. Werner de Castro ◽  
Simone Appenzeller ◽  
Manoel B. B�rtolo ◽  
L�lian Tereza Lavras Costallat
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Protein Losing Enteropathy

Missed hypereosinophilic syndrome in a critically ill patient with systemic lupus erythematosus

2021 ◽  
Vol 14 (1) ◽  
pp. e236592
Author(s):  
Ying Ling ◽  
Mary Jane Bell ◽  
Lisa Chodirker ◽  
Shirley Lake
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Hypereosinophilic Syndrome ◽  
Clinical Manifestations ◽  
Critically Ill Patient ◽  
Total Leucocyte Count ◽  
High Dose ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus

A high functioning 74-year-old man with systemic lupus erythematosus presented to the emergency department with acute anxiety. He was found to have elevated cardiac enzymes and admitted to the cardiology service for investigation. In hospital, he developed an erythematous papular rash, and deteriorated to being somnolent and bedridden. He was found to have new multiterritory ischaemic strokes. It was eventually noted that he had persistent eosinophilia, present even on admission, which had been overlooked as the total leucocyte count was normal. Serology for antiphospholipid antibody syndrome (APS) was positive. He was diagnosed with hypereosinophilic syndrome (HES) secondary to new APS, and responded to high-dose steroids. This case highlights the importance of fully evaluating a leucocyte differential to make a diagnosis of HES. We discuss the definition, clinical manifestations, diagnostic approach and management of this important condition.

PROTEIN-LOSING ENTEROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS

1988 ◽  
Vol 18 (7) ◽  
pp. 868-871 ◽  
Author(s):  
S. E. J. EDMUNDS ◽  
V. GANJU ◽  
B. R. BEVERIDGE ◽  
M. A. FRENCH ◽  
M. F. QUINLAN
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Protein Losing Enteropathy
Sign in / Sign up

Export Citation Format

Share Document